Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Company profile
Ticker
BPTSY
Exchange
Website
CEO
Mr. Stanislas Veillet Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
resTORbio, Inc.
SEC CIK
BPTSY stock data
Latest filings (excl ownership)
6-K
Interim Financial Report
30 Sep 24
6-K
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
22 Jul 24
6-K
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
11 Jul 24
6-K
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris
1 Jul 24
25-NSE
Exchange delisting
28 Jun 24
6-K
All resolutions presented by the Company have been adopted
26 Jun 24
6-K
Current report (foreign)
20 Jun 24
6-K
Biophytis extends its contract with Atlas to secure financing for its business activities
20 Jun 24
6-K
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens
14 Jun 24
6-K
Biophytis announces filing of an IND application
11 Jun 24
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Proequities | 0.00 | $0.00 |